These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 16901468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M.
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [Abstract] [Full Text] [Related]

  • 3. Prospects for antiapoptotic drug therapy of neurodegenerative diseases.
    Waldmeier PC.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):303-21. PubMed ID: 12657369
    [Abstract] [Full Text] [Related]

  • 4. Caspases and neuroprotection.
    Bilsland J, Harper S.
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1745-52. PubMed ID: 12528311
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M, Verdaguer E, Jordà EG, Jiménez A, Canudas AM, Camins A.
    Med Hypotheses; 2005 Dec; 64(1):120-3. PubMed ID: 15533627
    [Abstract] [Full Text] [Related]

  • 7. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?
    Waldmeier PC, Tatton WG.
    Drug Discov Today; 2004 Mar 01; 9(5):210-8. PubMed ID: 14980539
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M, Maruyama W.
    Expert Rev Neurother; 2009 Aug 01; 9(8):1233-50. PubMed ID: 19673610
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.
    Nakaso K, Ito S, Nakashima K.
    Neurosci Lett; 2008 Feb 20; 432(2):146-50. PubMed ID: 18201823
    [Abstract] [Full Text] [Related]

  • 12. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K.
    Ann Neurol; 2003 Feb 20; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB, Geldenhuys WJ, Van der Schyf CJ.
    Parkinsonism Relat Disord; 2007 Feb 20; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [Abstract] [Full Text] [Related]

  • 16. Future strategies for neuroprotection in Parkinson's disease.
    Schapira AH.
    Neurodegener Dis; 2010 Feb 20; 7(1-3):210-2. PubMed ID: 20224288
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Survivin: a target from brain cancer to neurodegenerative disease.
    Baratchi S, Kanwar RK, Kanwar JR.
    Crit Rev Biochem Mol Biol; 2010 Dec 20; 45(6):535-54. PubMed ID: 20925597
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O, Wahlberg LU.
    Exp Neurol; 2008 Jan 20; 209(1):82-8. PubMed ID: 17963752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.